{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:23:37Z","timestamp":1771935817115,"version":"3.50.1"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bronchiectasis is a complex and heterogeneous disease, and our current understanding of its pathophysiological mechanisms remains in its infancy. Currently, few specifically approved treatments for non-cystic fibrosis bronchiectasis are applied globally, and most guideline-recommended therapies have limited evidence of efficacy. Consequently, the development of new treatment methods is particularly urgent. To gain insight into new drugs under clinical development for adults with bronchiectasis, we conducted a review of the scientific literature and clinical trial registries. In this review, we discuss in detail the mechanisms and potential effects of these emerging therapies, which focus on their anti-inflammatory effects, enhancement of mucociliary clearance, and anti-infectious effects. Clinical research has revealed significant variability among patients, suggesting the need for a multidisciplinary and comprehensive approach. Future efforts should focus on patient stratification using biomarkers and clinical assessments, with an emphasis on precision medicine. Furthermore, it is essential to develop new antibiotics, innovative neutrophil-targeted therapies, and effective mucus-clearing agents to alleviate patient disease burden and minimize the risk of exacerbations.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1735598","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T05:33:48Z","timestamp":1771392828000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapies for bronchiectasis: mechanisms and potential effects"],"prefix":"10.3389","volume":"17","author":[{"given":"Long","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-rui","family":"Zhu","sequence":"additional","affiliation":[{"name":"College of Medicine, Jinhua University of Vocational Technology","place":["Jinhua, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-hang","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine","place":["Jinhua, Zhejiang, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01033-2015","article-title":"Changes in the incidence, prevalence and mortality of bronchiectasis in the uk from 2004 to 2013: A population-based cohort study","volume":"47","author":"Quint","year":"2016","journal-title":"Eur Respir J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.07.014","article-title":"Characteristics and health-care utilization history of patients with bronchiectasis in us medicare enrollees with prescription drug plans, 2006 to 2014","volume":"154","author":"Henkle","year":"2018","journal-title":"Chest"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00334-2021","article-title":"Epidemiology and economic burden of bronchiectasis requiring hospitalisation in Singapore","volume":"7","author":"Phua","year":"2021","journal-title":"ERJ Open Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00499-2019","article-title":"Increasing bronchiectasis prevalence in Germany, 2009-2017: A population-based cohort study","volume":"54","author":"Ringshausen","year":"2019","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201511-740PS","article-title":"Bronchiectasis in China","volume":"13","author":"Lin","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.rmed.2016.10.014","article-title":"Prevalence and incidence of bronchiectasis in catalonia, Spain: A population-based study","volume":"121","author":"Monteagudo","year":"2016","journal-title":"Respir Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00081-2015","article-title":"The embarc european bronchiectasis registry: Protocol for an international observational study","volume":"2","author":"Chalmers","year":"2016","journal-title":"ERJ Open Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01657-2021","article-title":"Children's bronchiectasis education advocacy and research network (child-bear-net): An ers clinical research collaboration on improving outcomes of children and adolescents with bronchiectasis","volume":"58","author":"Chang","year":"2021","journal-title":"Eur Respir J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00258-8","article-title":"Developments and priorities in bronchiectasis research","volume":"11","author":"Mazulov","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012406.pub2","article-title":"Macrolide antibiotics for bronchiectasis","volume":"3","author":"Kelly","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00300-2022","article-title":"European respiratory society statement for defining respiratory exacerbations in children and adolescents with bronchiectasis for clinical trials","volume":"60","author":"Chang","year":"2022","journal-title":"Eur Respir J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the dpp-1 inhibitor brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.coph.2017.09.015","article-title":"Cftr potentiators: From bench to bedside","volume":"34","author":"Jih","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00185-2021","article-title":"Treatment of cystic fibrosis airway cells with cftr modulators reverses aberrant mucus properties via hydration","volume":"59","author":"Morrison","year":"2022","journal-title":"Eur Respir J"},{"key":"B15","first-page":"6","article-title":"Inflammation: A two-edged sword\u2013the model of bronchiectasis","volume":"147","author":"Cole","year":"1986","journal-title":"Eur J Respir Dis Suppl"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31767-7","article-title":"Advances in bronchiectasis: Endotyping, genetics, microbiome, and disease heterogeneity","volume":"392","author":"Flume","year":"2018","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13509","article-title":"Pathophysiology, causes and genetics of paediatric and adult bronchiectasis","volume":"24","author":"Bush","year":"2019","journal-title":"Respirology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-018-0042-3","article-title":"Bronchiectasis","volume":"4","author":"Chalmers","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-018-0638-0","article-title":"Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis","volume":"18","author":"Chandrasekaran","year":"2018","journal-title":"BMC pulmonary Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-2600(23)00304-1","article-title":"New developments in bronchiectasis","volume":"11","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2202819","article-title":"Bronchiectasis - a clinical review","volume":"387","author":"O'Donnell","year":"2022","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001289.pub2","article-title":"Mucolytics for bronchiectasis","volume":"2014","author":"Wilkinson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1730945","article-title":"Long-term antibiotics in bronchiectasis","volume":"42","author":"Suarez-Cuartin","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201605-1027OC","article-title":"Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis","volume":"195","author":"Chalmers","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202303-0499OC","article-title":"Inflammatory molecular endotypes in bronchiectasis: A european multicenter cohort study","volume":"208","author":"Choi","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0015-2023","article-title":"Basic, translational and clinical aspects of bronchiectasis in adults","volume":"32","author":"Chalmers","year":"2023","journal-title":"Eur Respir Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.164.9.2105083","article-title":"Bronchial inflammation and colonization in patients with clinically stable bronchiectasis","volume":"164","author":"Angrill","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.molimm.2012.09.011","article-title":"Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis","volume":"55","author":"Chalmers","year":"2013","journal-title":"Mol Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1055\/s-0041-1730891","article-title":"Pathophysiology of bronchiectasis","volume":"42","author":"Keir","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081065","article-title":"Neutrophil elastase and chronic lung disease","volume":"11","author":"Voynow","year":"2021","journal-title":"Biomolecules"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115996","article-title":"Protease-antiprotease imbalance in bronchiectasis","volume":"22","author":"Oriano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.615959","article-title":"The role of neutrophils and neutrophil elastase in pneumococcal pneumonia","volume":"11","author":"Domon","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2022.8549","article-title":"Sivelestat sodium attenuates acute lung injury by inhibiting jnk\/nf-kappab and activating nrf2\/ho-1 signaling pathways","volume":"23","author":"Zhang","year":"2023","journal-title":"Biomol BioMed"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00494-2021","article-title":"The emerging role of proteases in \u03b11-antitrypsin deficiency and beyond","volume":"7","author":"Fazleen","year":"2021","journal-title":"ERJ Open Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.pupt.2019.03.009","article-title":"Safety and efficacy of the human neutrophil elastase inhibitor bay 85\u20138501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial","volume":"56","author":"Watz","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2019.1630379","article-title":"A patenting perspective on human neutrophil elastase (hne) inhibitors (2014-2018) and their therapeutic applications","volume":"29","author":"Crocetti","year":"2019","journal-title":"Expert Opin Ther Pat"},{"key":"B37","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jcf.2019.08.020","article-title":"Single dose escalation studies with inhaled pol6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis","volume":"19","author":"Barth","year":"2020","journal-title":"J Cyst Fibros"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202306-532OC","article-title":"Optima: An open-label, noncomparative pilot trial of inhaled molgramostim in pulmonary nontuberculous mycobacterial infection","volume":"21","author":"Thomson","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"B39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bcp.2017.02.009","article-title":"Prolonged pharmacological inhibition of cathepsin c results in elimination of neutrophil serine proteases","volume":"131","author":"Guarino","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411664","article-title":"Phase 3 trial of the dpp-1 inhibitor brensocatib in bronchiectasis","volume":"392","author":"Chalmers","year":"2025","journal-title":"New Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-023-01774-4","article-title":"Bi 1291583: A novel selective inhibitor of cathepsin c with superior in vivo profile for the treatment of bronchiectasis","volume":"72","author":"Kreideweiss","year":"2023","journal-title":"Inflammation Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01551-2024","article-title":"Cathepsin c (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: Airleaf(r), a phase ii randomised, double-blind, placebo-controlled, dose-finding study","volume":"65","author":"Chalmers","year":"2024","journal-title":"Eur Respir J"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00148-2015","article-title":"A randomised, placebo-controlled study of the cxcr2 antagonist azd5069 in bronchiectasis","volume":"46","author":"De Soyza","year":"2015","journal-title":"Eur Respir J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.03.116","article-title":"Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases","volume":"9","author":"Kawamatawong","year":"2017","journal-title":"J Thorac Dis"},{"key":"B45","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1164\/rccm.202108-1889OC","article-title":"Characterization of eosinophilic bronchiectasis: A european multicohort study","volume":"205","author":"Shoemark","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2023.05.016","article-title":"Eosinophils in bronchiectasis: A u-turn for bronchiectasis management","volume":"164","author":"Pollock","year":"2023","journal-title":"CHEST"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00453-2020","article-title":"Blood eosinophils predict inhaled fluticasone response in bronchiectasis","volume":"56","author":"Aliberti","year":"2020","journal-title":"Eur Respir J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2022.10.027","article-title":"Significance and potential role of eosinophils in non-cystic fibrosis bronchiectasis","volume":"11","author":"Guan","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of copd exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12123953","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with co-presence of bronchiectasis: A real-world multicentre observational study","volume":"12","author":"Campisi","year":"2023","journal-title":"J Clin Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hct109","article-title":"Non-cystic fibrosis bronchiectasis","volume":"106","author":"McDonnell","year":"2013","journal-title":"QJM"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006316.pub3","article-title":"Pneumococcal vaccines for children and adults with bronchiectasis","volume":"2009","author":"Chang","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.47.0799","article-title":"Additive inoculation of influenza vaccine and 23-valent pneumococcal polysaccharide vaccine to prevent lower respiratory tract infections in chronic respiratory disease patients","volume":"47","author":"Sumitani","year":"2008","journal-title":"Intern Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4103\/atm.ATM_171_17","article-title":"The saudi thoracic society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis","volume":"12","author":"Al-Jahdali","year":"2017","journal-title":"Ann Thorac Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1136\/thx.2010.136119","article-title":"British thoracic society guideline for non-cf bronchiectasis","author":"Pasteur","year":"2010","journal-title":"Thorax"},{"key":"B56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000093933","article-title":"Double-blind study of om-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease","volume":"74","author":"Soler","year":"2007","journal-title":"Respiration"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-15-150","article-title":"To investigate the prevention of om-85 on bronchiectasis exacerbations (iprobe) in chinese patients: Study protocol for a randomized controlled trial","volume":"15","author":"Gao","year":"2014","journal-title":"Trials"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/82219","article-title":"Statins as a newly recognized type of immunomodulator","volume":"6","author":"Kwak","year":"2000","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70050-5","article-title":"Atorvastatin as a stable treatment in bronchiectasis: A randomised controlled trial","volume":"2","author":"Mandal","year":"2014","journal-title":"Lancet Respir Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2017.05.017","article-title":"A randomized controlled trial of atorvastatin in patients with bronchiectasis infected with pseudomonas aeruginosa: A proof of concept study","volume":"152","author":"Bedi","year":"2017","journal-title":"Chest"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e014613","DOI":"10.1136\/bmjopen-2016-014613","article-title":"Pseudomonas aeruginosa isolation in patients with non-cystic fibrosis bronchiectasis: A retrospective study","volume":"8","author":"Wang","year":"2018","journal-title":"BMJ Open"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12528","article-title":"Aetiology of bronchiectasis in guangzhou, southern China","volume":"20","author":"Guan","year":"2015","journal-title":"Respirology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/crj.13596","article-title":"Gender differences in clinical characteristics of patients with non-cystic fibrosis bronchiectasis in different age groups in northern China","volume":"17","author":"Zhou","year":"2023","journal-title":"Clin Respir J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2202OC","article-title":"Characterization of the \"frequent exacerbator phenotype\" in bronchiectasis","volume":"197","author":"Chalmers","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2017","article-title":"The independent contribution of pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis","volume":"51","author":"Araujo","year":"2018","journal-title":"Eur Respir J"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201506-333OC","article-title":"A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"B67","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12931-021-01729-5","article-title":"Risk factors for pseudomonas aeruginosa colonization in non-cystic fibrosis bronchiectasis and clinical implications","volume":"22","author":"Kwok","year":"2021","journal-title":"Respir Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00074605","article-title":"The effect of pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis","volume":"28","author":"Davies","year":"2006","journal-title":"Eur Respir J"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2020.04.007","article-title":"Pseudomonas aeruginosa and lung function decline in patients with bronchiectasis","volume":"27","author":"Martinez-Garcia","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1900594","article-title":"The contribution of pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: A prospective cohort study","volume":"53","author":"Wang","year":"2021","journal-title":"Ann Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0756OC","article-title":"A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis","volume":"183","author":"Murray","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201312-2208OC","article-title":"Inhaled colistin in patients with bronchiectasis and chronic pseudomonas aeruginosa infection","volume":"189","author":"Haworth","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.2.9910086","article-title":"Tobramycin solution for inhalation reduces sputum pseudomonas aeruginosa density in bronchiectasis","volume":"162","author":"Barker","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(14)70165-1","article-title":"Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (air-bx1 and air-bx2): Two randomised double-blind, placebo-controlled phase 3 trials","volume":"2","author":"Barker","year":"2014","journal-title":"Lancet Respir Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02053-2017","article-title":"Respire 2: A phase iii placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"Aksamit","year":"2018","journal-title":"Eur Respir J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02052-2017","article-title":"Respire 1: A phase iii placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur Respir J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with pseudomonas aeruginosa (orbit-3 and orbit-4): Two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013254.pub2","article-title":"Intermittent prophylactic antibiotics for bronchiectasis","volume":"1","author":"Spencer","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03675-z","article-title":"Predicting factors for chronic colonization of pseudomonas aeruginosa in bronchiectasis","volume":"38","author":"Pieters","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.11.018","article-title":"Outcomes of pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis","volume":"106","author":"White","year":"2012","journal-title":"Respir Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00851-2016","article-title":"Efficacy of pseudomonas aeruginosa eradication regimens in bronchiectasis","volume":"49","author":"Vallieres","year":"2017","journal-title":"Eur Respir J"},{"key":"B82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1164\/rccm.201809-1651OC","article-title":"Airway bacterial load and inhaled antibiotic response in bronchiectasis","volume":"200","author":"Sibila","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/thoraxjnl-2018-212463","article-title":"British thoracic society guideline for bronchiectasis in adults","volume":"74","author":"Hill","year":"2019","journal-title":"Thorax"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017","article-title":"European respiratory society guidelines for the management of adult bronchiectasis","volume":"50","author":"Polverino","year":"2017","journal-title":"Eur Respir J"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04388-2020","article-title":"Feasibility of shortening intravenous antibiotic therapy for bronchiectasis based on bacterial load: A proof-of-concept randomised controlled trial","volume":"58","author":"Bedi","year":"2021","journal-title":"Eur Respir J"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(19)30191-2","article-title":"Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: An individual participant data meta-analysis","volume":"7","author":"Chalmers","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201601-044OC","article-title":"Macrolide treatment inhibits pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis. An analysis from the bronchiectasis and low-dose erythromycin study trial","volume":"13","author":"Burr","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.08.1451","article-title":"Macrolides for clinically significant bronchiectasis in adults: Who should receive this treatment","volume":"150","author":"Hill","year":"2016","journal-title":"Chest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.19-1-64","article-title":"Respiratory medicine: bronchiectasis","volume":"19","author":"Firth","year":"2019","journal-title":"Clin Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201906-1219OC","article-title":"Airway mucus hyperconcentration in non-cystic fibrosis bronchiectasis","volume":"201","author":"Ramsey","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008351.pub3","article-title":"Airway clearance techniques for bronchiectasis","volume":"2015","author":"Lee","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01926-2017","article-title":"Long-term benefits of airway clearance in bronchiectasis: A randomised placebo-controlled trial","volume":"51","author":"Mu\u00f1oz","year":"2018","journal-title":"Eur Respir J"},{"key":"B93","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.arbres.2017.07.015","article-title":"Spanish guidelines on the evaluation and diagnosis of bronchiectasis in adults","volume":"54","author":"Martinez-Garcia","year":"2018","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"Cftr modulator therapy: Transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/j.0009-9163.2004.00265.x","article-title":"Bronchiectasis in adult patients: An expression of heterozygosity for cftr gene mutations","volume":"65","author":"Casals","year":"2004","journal-title":"Clin Genet"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200909-1434OC","article-title":"Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis","volume":"181","author":"Bienvenu","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.020263","article-title":"Role of cftr mutations in adult bronchiectasis","volume":"59","author":"King","year":"2004","journal-title":"Thorax"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2013-0228OC","article-title":"Cystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis","volume":"50","author":"Lambert","year":"2014","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510095","article-title":"Hypertonic saline or carbocisteine in bronchiectasis","volume":"393","author":"Bradley","year":"2025","journal-title":"New Engl J Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1165\/rcmb.2019-0287OC","article-title":"Novel therapy of bicarbonate, glutathione, and ascorbic acid improves cystic fibrosis mucus transport","volume":"63","author":"Adewale","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2011.07.019","article-title":"Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis","volume":"105","author":"Kellett","year":"2011","journal-title":"Respir Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008649.pub4","article-title":"Inhaled mannitol for cystic fibrosis","volume":"5","author":"Nevitt","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2021.02.011","article-title":"Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study","volume":"20","author":"Flume","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/resp.13459","article-title":"Airway clearance, mucoactive therapies and pulmonary rehabilitation in bronchiectasis","volume":"24","author":"O'Neill","year":"2019","journal-title":"Respirology"},{"key":"B105","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1177\/1479972310391282","article-title":"Effects of pulmonary rehabilitation in bronchiectasis: A retrospective study","volume":"8","author":"Ong","year":"2011","journal-title":"Chron Respir Dis"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1159\/000380771","article-title":"Effects of pulmonary rehabilitation in patients with non-cystic fibrosis bronchiectasis: A retrospective analysis of clinical and functional predictors of efficacy","volume":"89","author":"Zanini","year":"2015","journal-title":"Respiration"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201309-1575OC","article-title":"The bronchiectasis severity index. An international derivation and validation study","volume":"189","author":"Chalmers","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-20-1282","article-title":"Effects of treatment with long-acting muscarinic antagonists (lama) and long-acting beta-agonists (laba) on lung function improvement in patients with bronchiectasis: An observational study","volume":"13","author":"Lee","year":"2020","journal-title":"J Thorac Dis"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-0180","article-title":"Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis","volume":"141","author":"Martinez-Garcia","year":"2012","journal-title":"Chest"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02184-2021","article-title":"Tiotropium treatment for bronchiectasis: A randomised, placebo-controlled, crossover trial","volume":"59","author":"Jayaram","year":"2022","journal-title":"Eur Respir J"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01079-2024","article-title":"Dual bronchodilators in bronchiectasis study: A randomised controlled trial","volume":"11","author":"Wilson","year":"2025","journal-title":"ERJ Open Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735598\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:30:55Z","timestamp":1771932655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1735598\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":111,"alternative-id":["10.3389\/fimmu.2026.1735598"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1735598","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"article-number":"1735598"}}